Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid. Read more about Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Read more about Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.
An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. Read more about An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.
Genetic Variability of the SARS-CoV-2 Pocketome. Read more about Genetic Variability of the SARS-CoV-2 Pocketome.
MYC protein interactors in gene transcription and cancer. Read more about MYC protein interactors in gene transcription and cancer.
Conformational plasticity of the ULK3 kinase domain. Read more about Conformational plasticity of the ULK3 kinase domain.
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors. Read more about Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors.
NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells. Read more about NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.
Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors. Read more about Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors.
Integrated analysis of Shank1 PDZ interactions with C-terminal and internal binding motifs. Read more about Integrated analysis of Shank1 PDZ interactions with C-terminal and internal binding motifs.
